Retatrutide is an investigational metabolic treatment currently in advanced clinical development. Created by Eli Lilly, it represents a new class of weight-management medication known as a triple agonist — a formulation engineered to activate three key hormonal pathways involved in appetite regulation, glucose balance and energy expenditure. Although early research has generated considerable global interest, Retatrutide has not yet received regulatory approval in Singapore or internationally.
At present, individuals seeking doctor-supervised weight loss must rely on treatments that are already approved and supported by extensive clinical evidence. These established medications form the foundation of medically supervised weight-management programmes in Singapore and include both injectable and oral GLP-1 therapies.
As global Phase 3 studies progress, upcoming data will help clarify how Retatrutide may integrate into structured doctor-led weight-loss programmes in Singapore once regulatory approvals are granted.
Retatrutide is an investigational injectable medication developed by Eli Lilly and studied as a potential next-generation therapy for medically supervised weight management. It belongs to a new class of multi-pathway metabolic agents known as triple agonists, meaning it is engineered to activate three key hormonal receptors involved in appetite control, glucose regulation and energy expenditure.
Unlike existing GLP-1–based therapies that act on a single pathway, or dual-agonist medications that stimulate two, Retatrutide is designed to target three receptors at once: GLP-1, GIP and glucagon. This expanded receptor profile reflects global scientific interest in exploring broader metabolic modulation for individuals requiring more comprehensive support for appetite regulation and fat-metabolism dynamics.
Early research indicates that Retatrutide’s triple-agonist mechanism may influence eating behaviour, caloric intake, metabolic rate and fat utilisation. As its clinical development progresses, Retatrutide has become one of the most closely observed investigational metabolic therapies internationally.
Retatrutide is unique because it stimulates GLP-1, GIP and glucagon receptors simultaneously.
This combined activity distinguishes Retatrutide from single-pathway GLP-1 therapies and dual-agonist medications such as tirzepatide.
GLP-1 medications available in Singapore — such as semaglutide — stimulate a single metabolic receptor. Dual-agonist therapies such as tirzepatide activate two. Retatrutide is engineered to activate three, creating a wider metabolic activation profile.
This expanded receptor targeting is being studied for its potential effects on appetite suppression, fat-metabolism pathways, energy expenditure and metabolic flexibility. Final conclusions will depend on the outcomes of Phase 3 trials, but Retatrutide represents a possible future evolution of GLP-1–based weight-management frameworks.
Retatrutide is being studied for its ability to modulate several metabolic pathways that influence appetite control, energy balance and fat-utilisation patterns. Unlike existing medications that act on a single receptor (GLP-1) or two receptors (GLP-1 and GIP), Retatrutide is engineered to activate three major hormonal pathways simultaneously. This triple-agonist design may offer a broader metabolic effect, which is one reason it has attracted significant global interest. Ongoing clinical trials are evaluating how this multi-pathway mechanism translates into meaningful and sustainable weight-management outcomes when used under medical supervision.
A large Phase 2 clinical study involving adults with overweight or obesity demonstrated clear dose-dependent weight-loss effects with Retatrutide. Participants receiving higher doses experienced more pronounced reductions in body weight, with a meaningful proportion achieving double-digit percentage weight loss over the treatment period.
In addition to measurable changes in weight, researchers observed improvements in appetite suppression, reductions in daily caloric intake and more consistent eating-behaviour patterns. These outcomes highlight the potential of triple-agonist therapy to modulate several metabolic pathways simultaneously, contributing to stronger treatment responses as doses increased.
Beyond weight reduction, early clinical findings indicated favourable changes in several metabolic health markers. Improvements were seen in fasting glucose, insulin sensitivity and lipid balance, suggesting that Retatrutide may provide broad metabolic support as part of its multi-pathway mechanism.
Some participants also demonstrated reductions in waist circumference and indicators of visceral adiposity, aligning with the potential metabolic effects associated with glucagon-receptor activation. Ongoing studies are assessing the consistency of these results across different dosing strategies, populations and treatment durations.
Retatrutide is currently progressing towards Phase 3 clinical evaluation, where larger study populations, extended treatment periods and structured monitoring will provide greater clarity on its long-term safety and efficacy. These trials will assess the durability of weight-loss results, metabolic stability and the overall clinical impact of triple-agonist therapy.
Once Phase 3 outcomes are completed and reviewed, regulatory agencies will determine its suitability for approval. These findings will guide how Retatrutide may eventually be incorporated into doctor-supervised weight-management programmes in Singapore and internationally.
As clinical research progresses, Retatrutide is being explored for several potential advantages arising from its triple-agonist structure. By simultaneously activating the GLP-1, GIP and glucagon receptors, the medication engages multiple hormonal pathways involved in appetite regulation, metabolic processing and fat-utilisation mechanisms. This multi-receptor approach represents an expanded direction in metabolic therapy and differs fundamentally from current single-agonist GLP-1 medications and dual-agonist treatments.
Initial studies have shown that gastrointestinal symptoms such as nausea, decreased appetite, diarrhoea and mild abdominal discomfort may occur during the early stages of treatment or during dose escalation. These effects are frequently observed with GLP-1–based medications and typically lessen as the body adjusts to receptor stimulation. Ongoing research is evaluating how different dosing regimens of Retatrutide influence tolerability during the initial weeks of therapy.
Retatrutide’s triple-agonist mechanism includes activation of the glucagon receptor, which introduces additional metabolic considerations not present in single- or dual-pathway treatments. Glucagon signalling may affect glucose regulation, energy expenditure and heart-rate patterns. Current trials incorporate detailed metabolic and cardiovascular monitoring to determine how glucagon-receptor engagement influences individual response and whether certain patients may require closer supervision.
Retatrutide is not approved for use in Singapore or in any other country. It remains an investigational medication undergoing advanced Phase 3 clinical trials to evaluate its long-term safety, dosing suitability, metabolic effects and potential role in doctor-supervised weight management. Until these studies are completed and reviewed by regulatory authorities, Retatrutide cannot be prescribed, dispensed or supplied by licensed medical clinics.
Because it is still under clinical evaluation, there are no authorised pharmaceutical distribution channels for Retatrutide. Any overseas listings, online advertisements or grey-market offers should be avoided, as these unverified products may pose significant safety risks and do not meet regulatory standards.
As Retatrutide moves through late-stage clinical development, emerging research is offering insights into the potential patient groups that may benefit from its triple-agonist mechanism in the future. Although the medication is not yet approved in Singapore, early studies suggest that its multi-receptor activity may support adults who require broader metabolic regulation within a medically supervised weight-management programme. Final suitability will depend on regulatory approval, published clinical guidelines and an individualised assessment by a qualified doctor.
Although Retatrutide is still undergoing clinical investigation and is not yet available for prescription use, several well-established medical treatments are already approved in Singapore for doctor-supervised weight management. These therapies work through validated metabolic pathways that help regulate appetite, enhance satiety and support sustained reductions in caloric intake. They form the foundation of structured medical weight-loss programmes and are prescribed based on individual health profiles, treatment goals and clinical suitability.
Ozempic, which contains semaglutide, is a weekly injectable GLP-1 receptor agonist used to support appetite regulation and improve metabolic stability. It has undergone extensive global evaluation and is widely prescribed as part of medically supervised weight-loss plans in suitable adults. More information is available here.
Wegovy is a higher-dose semaglutide formulation specifically approved for chronic weight management. It is administered once weekly and is supported by substantial clinical data demonstrating significant and sustained reductions in body weight among adults with overweight or obesity. Further details can be found here.
Mounjaro, which contains tirzepatide, activates both the GLP-1 and GIP receptors. This dual-pathway mechanism helps regulate appetite and supports favourable metabolic responses, making it an advanced option for medically supervised weight-loss programmes where clinically appropriate. More information is available here.
Rybelsus is the only oral GLP-1 medication currently approved in Singapore. It is formulated as an oral version of semaglutide and offers a non-injectable alternative for individuals who prefer daily tablets while still benefiting from appetite-regulating and metabolic effects under medical supervision. Learn more here.
Patients considering future medical weight-management options often have questions about Retatrutide, its current approval status, clinical findings and how it may eventually fit within doctor-supervised programmes. The following FAQs reflect the most up-to-date understanding from ongoing research.
